Document Detail

Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls.
MedLine Citation:
PMID:  9520071     Owner:  NLM     Status:  MEDLINE    
So far, the pathogenic significance and use for diagnosis of antiganglioside GM1 antibodies (anti-GM1) are unclear. We therefore compared serum IgM and IgG antimonosialo ganglioside GM1 levels of 33 patients with presumed immune-mediated neuropathies, 100 patients with various other central or peripheral neurological disorders, and 110 controls by ELISA. We also measured the complement-activating capacity of anti-GM1 by C5b-9-GM1-ELISA to evaluate its value to distinguish between pathogenic and nonpathogenic autoantibodies. Low levels of anti-GM1 were observed in all disease categories and in controls (healthy blood donors). Twenty-four of the controls including the 10 with the highest serum IgM or IgG anti-GM1 were examined for neurological disorders in a double-blind checkup study. In the patients, elevated IgM anti-GM1 levels were predominantly found in those with neuropathies (NP), but barely in patients with central nervous system disease (CNSD). We found elevated IgG anti-GM1 levels predominantly in patients with NP of inflammatory origin (multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy or Guillain-Barré syndrome), rarely in patients with NP of noninflammatory origin or CNSD, but not in the control disease group myasthenia gravis (MG). Median levels of IgM-, IgG-, (IgM+IgG)-, and C5b-9-binding anti-GM1 were significantly higher in patients with inflammatory NP as compared to the controls (p < 0.025). In addition, median levels of IgG- and (IgM+IgG)-anti-GM1 were significantly higher in inflammatory NP versus CNSD. Elevated complement-binding activity was associated with low or elevated IgM and/or IgG anti-GM1. Nevertheless, there was a significant correlation between anti-GM1 level (IgM+IgG) and the respective complement-activating capacity (r = 0.758; n = 243). Estimation of anti-GM1 and their respective complement-activating capacity may be helpful in the diagnosis of inflammatory neuropathies. However, neither an elevated anti-GM1 level nor an increased C5b-9 binding seems specific for a given disease category (e.g. peripheral nerve disease) nor a disease process (e.g. demyelination or inflammation).
E Uetz-von Allmen; M Sturzenegger; R Rieben; F Rihs; A Frauenfelder; U E Nydegger
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European neurology     Volume:  39     ISSN:  0014-3022     ISO Abbreviation:  Eur. Neurol.     Publication Date:  1998  
Date Detail:
Created Date:  1998-05-27     Completed Date:  1998-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0150760     Medline TA:  Eur Neurol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  103-10     Citation Subset:  IM    
Regional Red Cross Blood Transfusion Center, Bern, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blood Donors
Case-Control Studies
Central Nervous System Diseases / immunology*
Complement Activation / immunology*
Complement Membrane Attack Complex / biosynthesis
Enzyme-Linked Immunosorbent Assay
G(M1) Ganglioside / immunology*
Immunoglobulin G / blood*
Immunoglobulin M / blood*
Middle Aged
Peripheral Nervous System Diseases / immunology*
Reg. No./Substance:
0/Complement Membrane Attack Complex; 0/Immunoglobulin G; 0/Immunoglobulin M; 37758-47-7/G(M1) Ganglioside

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypertrophy of the inferior olivary nucleus in patients with progressive supranuclear palsy.
Next Document:  Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's dise...